Wall Street analysts predict that Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) will post earnings per share of ($0.22) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Synergy Pharmaceuticals’ earnings. Synergy Pharmaceuticals reported earnings of ($0.23) per share in the same quarter last year, which would suggest a positive year over year growth rate of 4.3%. The company is expected to report its next quarterly earnings report on Monday, August 14th.

According to Zacks, analysts expect that Synergy Pharmaceuticals will report full-year earnings of ($0.72) per share for the current year, with EPS estimates ranging from ($0.90) to ($0.47). For the next fiscal year, analysts expect that the firm will post earnings of ($0.14) per share, with EPS estimates ranging from ($0.50) to $0.07. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Synergy Pharmaceuticals.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.07. The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.10 million.

A number of analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $9.00 target price on shares of Synergy Pharmaceuticals in a research note on Tuesday. Canaccord Genuity reiterated a “buy” rating and issued a $13.00 price objective on shares of Synergy Pharmaceuticals in a research report on Monday, July 10th. Zacks Investment Research lowered Synergy Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Citigroup Inc. restated a “sell” rating and set a $3.70 target price on shares of Synergy Pharmaceuticals in a report on Wednesday, June 28th. Finally, BTIG Research restated a “buy” rating and set a $11.00 target price on shares of Synergy Pharmaceuticals in a report on Tuesday, June 27th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $10.67.

Synergy Pharmaceuticals (NASDAQ SGYP) traded up 1.43% during trading on Thursday, hitting $4.27. 2,626,618 shares of the stock traded hands. Synergy Pharmaceuticals has a one year low of $3.34 and a one year high of $7.15. The stock’s market cap is $960.53 million. The company has a 50-day moving average price of $4.29 and a 200 day moving average price of $4.90.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/20/synergy-pharmaceuticals-inc-sgyp-expected-to-post-earnings-of-0-22-per-share.html.

A number of institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. bought a new stake in shares of Synergy Pharmaceuticals during the fourth quarter valued at $1,162,000. State Street Corp boosted its stake in Synergy Pharmaceuticals by 11.6% in the fourth quarter. State Street Corp now owns 6,283,669 shares of the biopharmaceutical company’s stock valued at $38,270,000 after buying an additional 653,353 shares in the last quarter. Tudor Investment Corp Et Al boosted its stake in Synergy Pharmaceuticals by 1.3% in the fourth quarter. Tudor Investment Corp Et Al now owns 18,376 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 232 shares in the last quarter. Teachers Advisors LLC boosted its stake in Synergy Pharmaceuticals by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 298,781 shares of the biopharmaceutical company’s stock valued at $1,820,000 after buying an additional 11,521 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Synergy Pharmaceuticals by 9.1% in the first quarter. Nationwide Fund Advisors now owns 301,829 shares of the biopharmaceutical company’s stock valued at $1,407,000 after buying an additional 25,113 shares in the last quarter. 67.37% of the stock is owned by institutional investors and hedge funds.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Get a free copy of the Zacks research report on Synergy Pharmaceuticals (SGYP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.